Neuropediatrics 2020; 51(03): 211-214
DOI: 10.1055/s-0039-3400975
Short Communication
Georg Thieme Verlag KG Stuttgart · New York

Cerebral Insufficiency Caused by Diazoxide in a Premature Neonate with Congenital Hyperinsulinism

Seigo Okada*
1   Department of Pediatrics, Saiseikai Shimonoseki General Hospital, Shimonoseki, Yamaguchi, Japan
2   Department of Pediatrics, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan
,
Shinnosuke Fukunaga*
1   Department of Pediatrics, Saiseikai Shimonoseki General Hospital, Shimonoseki, Yamaguchi, Japan
,
Haruka Ohta
1   Department of Pediatrics, Saiseikai Shimonoseki General Hospital, Shimonoseki, Yamaguchi, Japan
,
Takashi Furuta
1   Department of Pediatrics, Saiseikai Shimonoseki General Hospital, Shimonoseki, Yamaguchi, Japan
2   Department of Pediatrics, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan
,
Reiji Hirano
1   Department of Pediatrics, Saiseikai Shimonoseki General Hospital, Shimonoseki, Yamaguchi, Japan
,
Takahiro Motonaga
1   Department of Pediatrics, Saiseikai Shimonoseki General Hospital, Shimonoseki, Yamaguchi, Japan
,
Yuichi Ishikawa
1   Department of Pediatrics, Saiseikai Shimonoseki General Hospital, Shimonoseki, Yamaguchi, Japan
› Author Affiliations
Further Information

Publication History

14 July 2019

06 October 2019

Publication Date:
27 November 2019 (online)

Abstract

Diazoxide is a peripheral vasodilator that has been used for intravenous treatment of hypertensive emergencies. However, it is currently used mainly for hyperinsulinemic hypoglycemia in lower dose orally, and its major side effects are edema and pulmonary hypertension. Herein, we report the first association between periventricular leukomalacia (PVL) and intractable hypotension due to diazoxide. A Japanese female premature infant showed hypoglycemia concomitant with hyperinsulinemia. She was diagnosed with congenital hyperinsulinism, and oral diazoxide was started. Six days after starting diazoxide, she suddenly showed peripheral coldness, oliguria, and severe hypotension. The hypotension was refractory to general vasopressor therapies and persisted even after the discontinuation of diazoxide. Cranial echography showed periventricular echodensities followed by cystic PVL. Low-dose vasopressin effectively treated the hypotension. This single case reminds us the serious adverse events of diazoxide that have been forgotten, especially in premature neonates.

* S. Okada and S. Fukunaga contributed equally to this study.


Financial Support

This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.


Authors' Contribution

S.O. led conceptualization and design of the analysis, analyzed and interpreted data, and drafted the initial manuscript. S.F. led conceptualization and design of the analysis, analyzed and interpreted data, supervised data collection, reviewed the manuscript critically, and approved the final manuscript as submitted. H.O., T.F., R.H., T.M., and Y.I. contributed to data collection and critically reviewed the manuscript.


 
  • References

  • 1 Herrera A, Vajravelu ME, Givler S. , et al. Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide. J Clin Endocrinol Metab 2018; 103 (12) 4365-4372
  • 2 Yorifuji T, Horikawa R, Hasegawa T. , et al; (on behalf of The Japanese Society for Pediatric Endocrinology and The Japanese Society of Pediatric Surgeons). Clinical practice guidelines for congenital hyperinsulinism. Clin Pediatr Endocrinol 2017; 26 (03) 127-152
  • 3 Fukutomi M, Shimodera M, Maeda Y, Iwakura M, Hara M. Safety and effectiveness, including intelligence prognosis, of diazoxide in pediatric patients with hyperinsulinemic hypoglycemia: special survey in Japan (long-term, all-case survey). Clin Pediatr Endocrinol 2018; 27 (03) 131-143
  • 4 Hu S, Xu Z, Yan J. , et al. The treatment effect of diazoxide on 44 patients with congenital hyperinsulinism. J Pediatr Endocrinol Metab 2012; 25 (11-12): 1119-1122
  • 5 Stanley CA. Hypoglycemia in the neonate. Pediatr Endocrinol Rev 2006; 4 (Suppl. 01) 76-81
  • 6 Diazoxide. Available at: https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/diazoxide . Accessed July 14, 2019
  • 7 Yoshida K, Kawai M, Marumo C. , et al. High prevalence of severe circulatory complications with diazoxide in premature infants. Neonatology 2014; 105 (03) 166-171
  • 8 Kawai M. Late-onset circulatory collapse of prematurity. Pediatr Int (Roma) 2017; 59 (04) 391-396
  • 9 Kumar GK, Dastoor FC, Robayo JR, Razzaque MA. Side effects of diazoxide. JAMA 1976; 235 (03) 275-276
  • 10 Mizroch S, Yurasek M. Hypotension and bradycardia following diazoxide and hydralazine therapy. JAMA 1977; 237 (23) 2471-2472
  • 11 Krishnamoorthy V, Chaikittisilpa N, Kiatchai T, Vavilala M. Hypertension after severe traumatic brain injury: friend or foe?. J Neurosurg Anesthesiol 2017; 29 (04) 382-387
  • 12 Pruitt AW, Dayton PG. A comparison of the binding of drugs to adult and cord plasma. Eur J Clin Pharmacol 1971; 4 (01) 59-62
  • 13 Biban P, Gaffuri M. Vasopressin and terlipressin in neonates and children with refractory septic shock. Curr Drug Metab 2013; 14 (02) 186-192
  • 14 Neonatal Research Network of Japan Database. Available at: http://plaza.umin.ac.jp/nrndata/indexe.htm . Accessed September 12, 2019
  • 15 Huang J, Zhang L, Kang B. , et al. Association between perinatal hypoxic-ischemia and periventricular leukomalacia in preterm infants: a systematic review and meta-analysis. PLoS One 2017; 12 (09) e0184993